Karyopharm Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
12/05/2025 22:02
Karyopharm Therapeutics Inc KPTI.OQ reported a quarterly adjusted loss of $2.77 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-4.80. The mean expectation of seven analysts for the quarter was for a loss of $4.18 per share. Wall Street expected results to range from $-4.56 to $-3.67 per share. Revenue fell 9.4% to $30.02 million from a year ago; analysts expected $35.24 million. Karyopharm Therapeutics Inc's reported EPS for the quarter was a loss of $2.77. The company reported a quarterly loss of $23.46 million. Karyopharm Therapeutics Inc shares had risen by 60.7% this quarter and lost 40.8% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 7.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $55.00 This summary was machine generated from LSEG data May 12 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -4.18 | -2.77 | Beat |
| Dec. 31 2024 | -3.92 | -3.60 | Beat |
| Sep. 30 2024 | -3.94 | -3.90 | Beat |
| Jun. 30 2024 | -4.48 | 2.25 | Beat |
Recent news on Karyopharm Therapeutics
See all newsBrief: Karyopharm Therapeutics - Enters Forbearance Agreement And Waiver On Sept 10, 2026 - SEC Filing
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview